Tag : HER2

Latest News

Data from NantHealth’s GPS Cancer platform reveals increased opportunities for HER2 directed therapy in colorectal cancer patients

Newsemia
SAN FRANCISCO–(BUSINESS WIRE)–NantHealth, Inc. (NASDAQ: NH), a next-generation, evidence-based, personalized healthcare company, today announced Results of a fifty-gene breast cancer RNA subtype classifier applied to...
Latest News

Biosimilar for HER2+ breast cancer achieves similar overall response rate to reference drug

Newsemia
The trastuzumab biosimilar HLX02 achieved similar overall response rate to reference trastuzumab in women with human epidermal growth factor receptor 2-positive (HER2+) recurrent or previously...
Latest News

HER2 (Human Epidermal Growth Factor Receptor 2) Inhibitors: Analysis on the Global Market by Product & Geography (2019-2023) – ResearchAndMarkets.com

Newsemia
DUBLIN–(BUSINESS WIRE)–The "HER2 (Human Epidermal Growth Factor Receptor 2) Inhibitors Market by Product and Geography – Global Forecast and Analysis 2019-2023" report has been added...
Latest News

Pfizer Presents Overall Survival Data From PALOMA-3 Trial of IBRANCE® (palbociclib) in Patients With HR+, HER2- Metastatic Breast Cancer

Newsemia
NEW YORK–(BUSINESS WIRE)–Pfizer Inc.(NYSE:PFE) today announced detailed overall survival (OS) data from the PALOMA-3 trial, which evaluated IBRANCE® (palbociclib) in combination with fulvestrant compared to...

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy